A 28-year-old woman from an endemic area (Jharkhand) presents with fever, splenomegaly, and anemia (Hb 7.5 g/dL). Bone marrow aspiration shows amastigotes confirming kala-azar. Which investigation is most appropriate to assess disease severity and monitor treatment response?

Explanation

## Monitoring Treatment Response in Kala-azar **Key Point:** Quantitative PCR (qPCR) is the most objective, sensitive, and rapid method to monitor parasite burden and assess treatment response in visceral leishmaniasis. ### Why qPCR for Treatment Monitoring? qPCR quantifies *Leishmania* DNA copy numbers in bone marrow or blood, providing: - **Objective parasite burden measurement** (baseline and post-treatment) - **Early detection of treatment failure** (before clinical relapse) - **Rapid turnaround** (24–48 hours vs. weeks for culture) - **Correlation with clinical outcomes** better than serology **High-Yield:** A ≥100-fold reduction in parasite load by qPCR indicates adequate treatment response and predicts clinical cure. Persistent or rising parasite DNA suggests treatment failure or relapse. ### Comparison of Monitoring Methods | Method | Sensitivity | Speed | Objective | Clinical Use | | --- | --- | --- | --- | --- | | **qPCR** | Very high | 24–48 h | Yes | Gold standard for monitoring | | Splenic index | Moderate | Days | Partial | Assesses organomegaly regression | | Repeat marrow smear | Moderate | Days | Yes | Cumbersome; rarely done | | rK39 serology | Low | Days | No | Remains positive for months; not useful for monitoring | **Clinical Pearl:** In clinical trials and reference centers, qPCR is now the preferred endpoint for assessing cure in kala-azar. A negative qPCR at 6 months post-treatment predicts sustained cure. ### Treatment Monitoring Algorithm ```mermaid flowchart TD A[Kala-azar confirmed by marrow smear]:::outcome --> B[Baseline qPCR of bone marrow/blood]:::action B --> C[Start antileishmanial therapy]:::action C --> D[qPCR at end of treatment]:::decision D -->|≥100-fold reduction| E[Cure achieved]:::outcome D -->|<100-fold reduction| F[Treatment failure]:::urgent F --> G[Switch to alternative regimen]:::action E --> H[qPCR at 6 months follow-up]:::decision H -->|Negative| I[Sustained cure]:::outcome H -->|Positive| J[Relapse]:::urgent ``` **Mnemonic:** **qPCR** = **q**uantitative **P**arasite **C**opy **R**eduction (best marker of treatment success). [cite:Park 26e Ch 8; WHO guidelines on leishmaniasis]